Metabolism and pharmacokinetics of ibuprofen

Aspirin and Related Drugs

Volumn , Issue , 2016, Pages 157-180

  Graham, G G ^a   Williams, K M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84981523505     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (163)

1. Aarons, L., Grennan, D.M., Rajapakse, C., Brinkley, J., Siddiqui, M., Taylor, L. and Higham, C. 1983a, Anti-inflammatory (ibuprofen) drug therapy in rheumatoid arthritis - rate of response and lack of time dependency of plasma pharmacokinetics. British Journal of Clinical Pharmacology, 15: 387-388.
2. Aarons, L., Grennan, D.M. and Siddiqui, M. 1983b, The binding of ibuprofen to plasma proteins. European Journal of Clinical Pharmacology, 25: 815-818.
3. Abernethy, D.R. and Greenblatt, D.J. 1985, Ibuprofen disposition in obese individuals. Arthritis and Rheumatism, 28: 1117-1121.
4. Adams, S.S., Cliffe, E.E., Lessel, B. and Nicholson, J.S. 1967, Some biological properties of 2-(4- isobutylphenyl)-propionic acid. Journal of Pharmaceutical Sciences, 56: 1686.
5. Adams, S.S., Bough, R.G., Cliffe, E.E., Lessel, B. and Mills, R.F.N. 1969a, Absorption, distribution and toxicity of ibuprofen. Toxicology and Applied Pharmacology, 15: 310-330.
6. Adams, S.S., McCullough, K.F. and Nicholson, J.S. 1969b, The pharmacological properties of ibuprofen, an antiinflammatory analgesic and antipyretic agent. Archives Internationales de Pharmacodynamie et de Thérapie, 178: 115-129.
7. Adams, S.S., Bough, R.G., Cliffe, E.E., Dickinson, W., Lessel, B., McCullough, K.F., et al. 1970, Some aspects of the pharmacology, metabolism, and toxicology of ibuprofen. Rheumatology and Physical Medicine, 10 (Suppl.): 9-22.
8. Adamska-Dyniewska, H., Tkaczewski, W. and Gajewska, B. 1982, Ibuprofen pharmacokinetics in patients with liver cirrhosis. Wiadomosci Lekarskie, 35: 609-613.
9. Ahn, H.Y., Amidon, G.L. and Smith, D.E. 1991b, Stereoselective systemic disposition of ibuprofen enantiomers in the dog. Pharmaceutical Research, 8: 1186-1190.
10. Ahn, H.Y., Jamali, F., Cox, S.R., Kittayanond, D. and Smith, D.E. 1991a, Stereoselective disposition of ibuprofen enantiomers in the isolated perfused rat kidney. Pharmaceutical Research, 8: 1520-1524.
11. Ahn, H.Y., Shiu, G.K., Trafton, W.F. and Doyle, T.D. 1994, Resolution of the enantiomers of ibuprofen; comparison study of diasterisomeric method and chiral stationary phase method. Journal of Chromatography B, 653: 163-169.
12. Albert, K.S., Gillespie, W.R., Wagner, J.G., Pau, A. and Lockwood, G.F. 1984, Effects of age on the clinical pharmacokinetics of ibuprofen. American Journal of Medicine, 77: 47-50.
13. al-Meshal, M.A., el-Sayed, Y.M., al-Balla, S.R. and Gouda, M.W. 1994, The effect of colestipol and cholestyramine on ibuprofen bioavailability in man. Biopharmaceutics and Drug Disposition, 15: 463-471.
14. Antal, E.J., Wright, C.E., Brown, B.L., Albert, K.S., Aman, L.C. and Levin, N.W. 1986, The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. Journal of Clinical Pharmacology, 26: 184-190.
15. Aranda, J.V., Varvarigou, A., Beharry, K., Bansal, R., Bardin, C., Modanlou, H., Papageorgiou, A. and Chemtob, S. 1997, Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatrica, 86: 289-293.
16. Askholt, J. and Nielsen-Kudsk, F. 1985, Ibuprofen, pharmacokinetics and pharmacodynamics in the isolated rabbit heart. Acta Pharmacologica et Toxicologica, 56: 99-107.
17. Au, D.S., Kuo, T.H., Mederski-Samoraj, B. and Lee, C.-S. 1984, Disposition of ibuprofen in nephrectomized dogs. Journal of Pharmaceutical Sciences, 73: 705-708.
18. Bannwarth, R., Lapicque, F., Pehourcq, F., Gillet, P., Schaeverbeke, T., Laborde, C., et al. 1995, Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. British Journal of Clinical Pharmacology, 40: 266-269.
19. Beck, W.S., Geisslinger, G., Engler, H. and Brune, K. 1991, Pharmacokinetics of ibuprofen enantiomers in dogs. Chirality, 3: 165-169.
20. Benabdeslam, H., Garcia, I., Bellon, G., Gilly, R. and Revol, R. 1998, Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. American Journal of Clinical Nutrition, 67: 912-918.
21. Bennett, M.J., Sherwood, W.G., Bhala, A. and Hale, D.E. 1992, Identification of urinary metabolites of (±/-)-2-(p-isobutylphenyl)propionic acid (Ibuprofen) by routine organic acid screening. Clinica Chimica Acta, 210: 55-62.
22. Bjornsdottir, I., Kepp, D.R., Tjornelund, J. and Hansen, S.H. 1998, Separation of the enantiomers of ibuprofen and its phase I major metabolites in urine using capillary electrophoresis. Electrophoresis, 19: 455-460.
23. Bradley, J.D., Rudy, A.C., Katz, B.P., Ryan, S.I., Kalasinski, L.A., Brater, D.C., et al. 1992, Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. Journal of Rheumatology, 19: 130-134.
24. Brown, R.D., Wilson, J.T., Kearns, G.L., Eichler, V.F., Johnson, V.A. and Bertrand, K.M. 1992, Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children. Journal of Clinical Pharmacology, 32: 231-241.
25. Bruggera, R., Reichel, C., Alia, B.G., Brune, K., Yamamoto, T., Tegeder, I. and Geisslinger, G. 2001, Expression of rat liver long-chain acyl-CoA synthetase and characterization of its role in the metabolism of R-ibuprofen and other fatty acid-like xenobiotics. Biochemical Pharmacology, 61: 651-656.
26. Brugueras, N.E., LeZotte, L.A. and Moxley, T.E. 1978, Ibuprofen: a double-blind comparison twice-aday therapy with four-times-a-day therapy. Clinical Therapeutics, 2: 13-21.
27. Castillo, M., Lam, F., Dooley, M.A., Stahl, E. and Smith, P.C. 1995, Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly. Clinical Pharmacology and Therapeutics, 57: 636-644.
28. Ceppi Monti, N., Gazzaniga, A., Gianesello, V., Stroppolo, F. and Lodola, E. 1992, Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. Arzneimittel-Forschung, 42: 556-559.
29. Chen, C.-S., Shieh, W.-R., Lu, P.-H., Harriman, S. and Chen, C.-Y. 1991, Metabolic stereoisomeric inversion of ibuprofen in mammals. Biochimica et Biophysica Acta, 1078: 411-417.
30. Chen, C.-Y. and Chen, C.-S. 1994, Stereoselective disposition of ibuprofen in patients with renal dysfunction. Journal of Pharmacology and Experimental Therapeutics, 268: 590-594.
31. Chen, C.-Y. and Chen, C.-S. 1995, Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. British Journal of Clinical Pharmacology, 40: 67-72.
32. Cheng, H., Rogers, J.D., Demetriades, J.L., Holland, S.D., Seibold, J.R. and Depuy, E. 1994, Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. Pharmaceutical Research, 11: 824-830.
33. Cox, J.W., Cox, S.R., VanGiessen, G. and Ruwart, M.J. 1985, Ibuprofen stereoisomer hepatic clearance and distribution in normal and fatty in situ perfused rat liver. Journal of Pharmacology and Experimental Therapeutics, 232: 636-643.
34. Cox, P.G.F., Moons, W.M., Russel, F.G.M. and van Ginneken, C.A.M. 1991, Renal handling and effects of S(±)-ibuprofen and R(-)-ibuprofen in the rat isolated perfused kidney. British Journal of Pharmacology, 103: 1542-1546.
35. Dawson, M., McGee, C.M., Vine, J.H., Watson, T.R. and Brooks, P.M. 1988, The disposition of biphenylacetic acid following topical application. European Journal of Clinical Pharmacology, 33: 639-642.
36. Day, R.O., Williams, K.M., Graham, G.G., Lee, E.J., Knihinicki, R.D. and Champion, G.D. 1988, Stereoselective disposition of ibuprofen enantiomers in synovial fluid. Clinical Pharmacology and Therapeutics, 43: 480-487.
37. Dietzel, K., Beck, W.S., Schneider, H.-T., Geisslinger, G. and Brune, K. 1990, The biliary and enterohepatic circulation of ibuprofen in rats. Pharmaceutical Research, 7: 87-90.
38. Dominkus, M., Nicolakis, M., Kotz, R., Wilkinson, F.E., Kaiser, R.R. and Chlud, K. 1996, Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittel-Forschung, 46: 1138-1143.
39. Dong, J.Q., Ni, L., Scott, C.S., Retsch-Bogart, G.Z. and Smith, P.C. 2000, Pharmacokinetics of ibuprofen enantiomers in children with cystic fibrosis. Journal of Clinical Pharmacology, 40: 861-868.
40. Dwivedi, S.K., Sattari, S., Jamali, F. and Mitchell, A.G. 1992, Ibuprofen racemate and enantiomers: phase diagram, solubility and thermodynamic studies. International Journal of Pharmaceutics, 87: 95-104.
41. Evans, A.M. 1996, Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(±)-ibuprofen. Journal of Clinical Pharmacology, 36: 7S-15S.
42. Evans, A.M., Nation, R.L. and Sansom, L.N. 1989a, Lack of effect of cimetidine on the pharmacokinetics of R(-)- and S(±)-ibuprofen. British Journal of Clinical Pharmacology, 28: 143-149.
43. Evans, A.M., Nation, R.L., Sansom, L.N., Bochner, F. and Somogyi, A.A. 1989b, Stereoselective plasma protein binding of ibuprofen enantiomers. European Journal of Clinical Pharmacology, 36: 283-290.
44. Evans, A.M., Nation, R.L., Sansom, L.N., Bochner, F. and Somogyi, A.A. 1990, The relationship between the pharmacokinetics of ibuprofen and the dose of racemic ibuprofen in humans. Biopharmaceutics and Drug Disposition, 11: 507-518.
45. Evans, A.M., Nation, R.L., Sansom, L.N., Bochner, F. and Somogyi, A.A. 1991, Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(±)- ibuprofen. British Journal of Clinical Pharmacology, 31: 131-138.
46. Fears, R. 1985, Lipophilic xenobiotic conjugates: the pharmacological and toxicological consequences of the participation of drugs and other foreign compounds as substrates in lipid biosynthesis. Progress in Lipid Research, 24: 177-195.
47. Fornasini, G., Monti, N., Brogin, G., Gallina, M., Eandi, M., Persiani, S., et al. 1997, Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. Chirality, 9: 297-302.
48. Garg, V. and Jusko, W.J. 1994, Pharmacodynamic modeling of non-steroidal anti-inflammatory drugs. Clinical Pharmacology and Therapeutics, 55: 87-88.
49. Geisslinger, G., Schuster, O., Stock, K.-P., Loew, D., Bach, G.L. and Brune, K. 1990, Pharmacokinetics of S(±)- and R(-)-ibuprofen in volunteers and first clinical experience of S(±)-ibuprofen in rheumatoid arthritis. European Journal of Clinical Pharmacology, 38: 493-497.
50. Geisslinger, G., Stock, K.-P., Loew, D., Bach, G.L. and Brune, K. 1993, Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology, 35: 603-607.
51. Gillespie, W.R., DiSanto, A.R., Monovich, R.E. and Albert, K.S. 1982, Relative bioavailability of commercially available ibuprofen oral dosage forms in humans. Journal of Pharmaceutical Sciences, 71: 1034-1038.
52. Gontarz, N., Small, R.E., Comstock, T.J., Stalker, D.J. and Willis, H.E. 1987, Effect of antacid suspension on pharmacokinetics of ibuprofen, Clinical Pharmacy, 6: 413-416.
53. Graham, G.G. 1988, Kinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Agents and Actions Supplements, 24: 66-75.
54. Greenblatt, D.J., Abernethy, D.R., Matlis, R., Harmatz, J.S. and Shader, R.I. 1984, Absorption and disposition of ibuprofen in the elderly. Arthritis and Rheumatism, 27: 1066-1069.
55. Grennan, D.M., Aarons, L., Siddiqui, M., Richards, M., Thompson, R. and Higham, C. 1983, Dose-response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. British Journal of Clinical Pharmacology, 15: 311-316.
56. Grennan, D.M., Ferry, D.G., Ashworth, M.E., Kenny, R.E. and MacKinnon, M. 1979, The aspirin-ibuprofen interaction in rheumatoid arthritis. British Journal of Clinical Pharmacology, 8: 497-503.
57. Gupta, M. and Majumdar, D.K. 1997, Effect of concentration, pH, and preservative on in vitro transcorneal permeation of ibuprofen and flurbiprofen from non-buffered aqueous drops. Indian Journal of Experimental Biology, 35: 844-849.
58. Hall, S.D., Hassanzadeh-Khayyat, M., Knadler, M.P. and Mayer, P.R. 1992, Pulmonary inversion of 2-arylpropionic acids: influence of protein binding. Chirality, 4: 349-352.
59. Hall, S.D., Rudy, A.C., Knight, P.M. and Brater, D.C. 1993, Lack of presystemic inversion of (R)- to (S)-ibuprofen in humans. Clinical Pharmacology and Therapeutics, 53: 393-400.
60. Hamman, M.A., Thompson, G.A. and Hall, S.D. 1997, Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochemical Pharmacology, 54: 33-41.
61. Hutt, A.J., Kooloobandi, A. and Hanlon, G.W. 1993, Microbial metabolism of 2-arylpropionic acids: chiral inversion of ibuprofen and 2-phenylpropionic acid. Chirality, 5: 596-601.
62. Iervolino, M., Cappello, B. Raghavan, S.L. and Hadgraft, J. 2001, Penetration enhancement of ibuprofen from supersaturated solutions through human skin. International Journal of Pharmaceutics, 212: 131-141.
63. Jamali, F. and Kunz-Dober, C.M. 1999, Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. British Journal of Clinical Pharmacology, 47: 391-396.
64. Jamali, F., Mehvar, R., Russell, A.S., Sattari, S., Yakimets, W.W. and Koo, J. 1992, Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. Journal of Pharmaceutical Sciences, 81: 221-225.
65. Jamali, F., Singh, N.N., Pasutto, F.M., Russell, A.S. and Coutts, R.T. 1988, Pharmacokinetics of ibuprofen enantiomers in humans following oral administration of tablets with different absorption rates. Pharmaceutical Research, 5: 40-43.
66. Jeffrey, P., Tucker, G.T., Bye, A., Crewe, H.K. and Wright, P.A. 1990, The site of inversion of R(-)- ibuprofen: studies using rat in-situ isolated perfused intestine/liver preparations. Journal of Pharmacy and Pharmacology, 43: 715-720.
67. Johnson, J.L., Brater, D.C. and Hall, S.D. 1995, Formation of 'hybrid' glycerolipids in normal volunteers. Clinical Pharmacology and Therapeutics, 57: 213.
68. Jones, K., Seymour, R.A. and Hawkesford, J.E. 1997, Are the pharmacokinetics of ibuprofen important determinants for the drug's efficacy in postoperative pain after third molar surgery?. British Journal of Oral and Maxillofacial Surgery, 35: 173-176.
69. Jørgensen, H.S., Christensen, H.R. and Kampmann, J.P. 1991, Interactions between digoxin and indomethacin or ibuprofen. British Journal of Clinical Pharmacology, 31: 108-110.
70. Juhl, R.P., Van Thiel, D.H., Dittert, L.W., Albert, K.S. and Smith, R.B. 1983, Ibuprofen and sulindac kinetics in alcoholic liver disease. Clinical Pharmacology and Therapeutics, 34: 104-109.
71. Kaiser, D.G. and Martin, R.S. 1978, Electron-capture GLC determination of ibuprofen in serum. Journal of Pharmaceutical Sciences, 67: 627-630.
72. Kaiser, D.G. and VanGiessen, G.J. 1974, GLC determination of ibuprofen [(α)-2-(p-isobutyl)propionic acid] in plasma. Journal of Pharmaceutical Sciences, 63: 219-221.
73. Kaiser, D.G., VanGiessen, G.J., Reischer, R.J. and Wechter, W.J. 1976, Isomeric inversion of ibuprofen (R)-enantiomer in humans. Journal of Pharmaceutical Sciences, 65: 269-273.
74. Kaplan, H.B., Edelson, H.S., Korchak, H.M., Given, W.P., Abramson, S. and Weissmann, G. 1984, Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo. Biochemical Pharmacology, 33: 371-378.
75. Kelley, M.T., Walson, P.D., Edge, J.H., Cox, S. and Mortensen, M.E. 1992, Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. Clinical Pharmacology and Therapeutics, 52: 181-189.
76. Kepp, D.R., Sidelmann, U.G. and Hansen, S.H. 1997, Isolation and characterization of major phase I and II metabolites of ibuprofen. Pharmaceutical Research, 14: 676-680.
77. Kirchheiner, J., Meineke, I., Freytag, G., Meisel, C., Roots, I. and Bröckmoller, J. 2002, Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clinical Pharmacology and Therapeutics, 72: 62-75.
78. Kleinbloesem, C.H., Ouwerkerk, M., Spitznagel, W., Wilkinson, F.E. and Kaiser, R.R. 1995, Pharmacokinetics and bioavailability of percutaneous ibuprofen. Arzneimittel-Forschung, 45: 1117-1121.
79. Knights, K.M. and Drew, R. 1992, The effects of ibuprofen enantiomers on hepatocyte intermediary metabolism and mitochondrial respiration. Biochemical Pharmacology, 44: 1291-1296.
80. Knights, K.M. and Jones, M.E. 1992, Inhibition kinetics of hepatic microsomal long chain fatty acid- CoA ligase by 2-arylpropionic acid non-steroidal anti-inflammatory drugs. Biochemical Pharmacology, 43: 1465-1471.
81. Knights, K.M., McLean, C.F., Tonkin, A.L. and Miners, J.O. 1995, Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in humans. British Journal of Clinical Pharmacology, 40: 153-156.
82. Knights, K.M., Talbot, U.M. and Baillie, T.A. 1992, Evidence of multiple forms of rat liver microsomal coenzyme A ligase catalysing the formation of 2-arylpropionyl-coenzyme A thioesters. Biochemical Pharmacology, 44: 2415-2417.
83. Knihinicki, R.D., Day, R.O., Graham, G.G. and Williams, K.M. 1990, Stereoselective disposition of ibuprofen and flurbiprofen in rats. Chirality, 2: 134-140.
84. Knihinicki, R.D., Williams, K.M. and Day, R.O. 1989, Chiral inversion of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs - 1 In vitro studies of ibuprofen and flurbiprofen. Biochemical Pharmacology, 38: 4389-4395.
85. Konstan, M.W., Byard, P.J. and Hoppel, C.L. 1995, Effect of high-dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine, 332: 848-854.
86. Konstan, M.W., Hoppel, C.L., Chai, B.L. and Davis, P.B. 1991, Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics, 118: 956-964.
87. Lapatto-Reiniluoto, O., Kivisto, K.T. and Neuvonen, P.J. 1999, Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram. British Journal of Clinical Pharmacology, 48: 148-153.
88. Laska, E.M., Sunshine, A., Marrero, I., Olson, N., Siegel, C. and McCormick, N. 1986, The correlation between blood levels of ibuprofen and clinical analgesic response. Clinical Pharmacology and Therapeutics, 40: 1-7.
89. Lee, E.J.D., Williams, K.M., Graham, G.G. and Champion, G.D. 1984, Liquid chromatographic determination and plasma concentration profile of the optical isomers of ibuprofen in man. Journal of Pharmaceutical Sciences, 73: 1542-1545.
90. Lee, E.J.D., Williams, K.M., Graham, G.G., Day, R.O. and Champion, G.D. 1985, Stereoselective disposition of ibuprofen enantiomers in man. British Journal of Clinical Pharmacology, 19: 669-674.
91. Leemann, T.D., Transon, C., Bonnabry, P. and Dayer, P. 1993, A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs under Experimental and Clinical Research, 19: 189-195.
92. Levine, M.A., Walker, S.E. and Paton, T.W. 1992, The effect of food or sucralfate on the bioavailability of S(±) and R(-) enantiomers of ibuprofen. Journal of Clinical Pharmacology, 32: 1110-1114.
93. Li, G., Treiber, G. and Klotz, U. 1989, The ibuprofen-cimetidine interaction. Stereochemical investigations. Drug Investigation, 1: 11-17.
94. Li, G., Treiber, G., Maier, K., Walker, S. and Klotz, U. 1993, Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. Clinical Pharmacokinetics, 25: 154-163.
95. Lockwood, G.F., Albert, K.S., Gillespie, W.R., Bole, G.G., Harkom, T.M., Szpunar, G.J. and Wagner, J.G. 1983, Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships. Clinical Pharmacology and Therapeutics, 34: 97-103.
96. Lockwood, G.F. and Wagner, J.G. 1982, High performance liquid chromatographic determination of ibuprofen and its major metabolites in biological fluids. Journal of Chromatography, 232: 335-343.
97. Longenecker, G.L., Swift, I.A., Bowen, R.J., Beyers, B.J. and Shah, A.K. 1985, Kinetics of ibuprofen effect on platelet and endothelial prostanoid release. Clinical Pharmacology and Therapeutics, 37: 343-348.
98. Martin, S.W., Stevens, A.J., Brennan, B.S., Rowland, M. and Houston, J.B. 1995, Pharmacodynamic comparison of regional drug delivery for non-steroidal anti-inflammatory drugs, using the rat airpouch model of inflammation. Journal of Pharmacy and Pharmacology, 47: 458-461.
99. Martin, W., Koselowske, G., Töberich, H., Kerkmann, T., Mangold, B. and Augustin, J. 1990, Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharmaceutics and Drug Disposition, 11: 265-278.
100. Mehvar, R. and Jamali, F. 1988, Pharmacokinetic analysis of the enantiomeric inversion of chiral nonsteroidal antiinflammatory drugs. Pharmaceutical Research, 5: 76-79.
101. Mehvar, R., Jamali, F. and Pasutto, F.M. 1988, Liquid-chromatographic assay of ibuprofen enantiomers in plasma. Clinical Chemistry, 34: 493-496.
102. Menzel, E.J. and Kolarz, G. 1994, Binding capacity of ibuprofen to muscle proteins. Arzneimittel- Forschung, 44: 341-343.
103. Menzel, S., Waibel, R., Brune, K. and Geisslinger, G. 1994, Is the formation of R-ibuprofenyladenylate the first stereoselective step of chiral inversion? Biochemical Pharmacology, 48: 1056-1058.
104. Menzel-Soglowek, S., Geisslinger, G. and Brune, K. 1990, Stereoselective high-performance liquid chromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral -acid glycoprotein column. Journal of Chromatography, 532: 295-303.
105. Menzel-Soglowek, S., Geisslinger, G., Mollenhauer, J. and Brune, K. 1992, Metabolic chiral inversion of 2-arylpropionates in rat H411E and human Hep G2 hepatoma cells. Relationship to in vivo metabolism. Biochemical Pharmacology, 43: 1487-1492.
106. Millership, J.S. and Collier, P.S. 1997, Topical administration of racemic ibuprofen. Chirality, 9: 313-316.
107. Mills, R.F.N., Adams, S.S., Cliffe, E.E., Dickinson, W. and Nicholson, J.S. 1973, The metabolism of ibuprofen. Xenobiotica, 3: 589-598.
108. Moorhouse, K.G., Dodds, P.F. and Hutson, D.H. 1991, Xenobiotic triacylglycerol formation in isolated hepatocytes. Biochemical Pharmacology, 41: 1179-1185.
109. Murray, M.D., Brater, D.C., Tierney, W.M., Hui, S.L. and McDonald, C.J. 1990, Ibuprofenassociated renal impairment in a large general internal medicine program. American Journal of Medical Science, 299: 222-229.
110. Murry, D.J., Oermann, C.M., Ou, C.N., Rognerud, C., Seilheimer, D.K. and Sockrider, M.M. 1999, Pharmacokinetics of ibuprofen in patients with cystic fibrosis. Pharmacotherapy, 19: 340-345.
111. Nahata, M.C., Durrell, D.E., Powell, D.A. and Gupta, N. 1991, Pharmacokinetics of ibuprofen in febrile children. European Journal of Clinical Pharmacology, 40: 427-428.
112. Naidong, W. and Lee, J.W. 1994, Development and validation of a liquid chromatographic method for the quantitation of ibuprofen enantiomers in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 12: 551-556.
113. Nakamura, Y., Yamaguchi, T., Takahashi, S., Hashimoto, S., Iwatami, K. and Nakagawa, Y. 1981, Optical isomerization mechanisms of R(-)-hydratropic acid derivatives. Journal of Pharmacobio-Dynamics, 4: S1.
114. Neuvonen, P.J. 1991, The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac. British Journal of Clinical Pharmacology, 31: 263-266.
115. Noctor, T.A.G., Felix, G. and Wainer, I.W. 1991, Stereochemical resolution of enantiomeric 2-aryl propionic acid non-steroidal anti-inflammatory drugs on a human serum albumin based highperformance liquid chromatographic chiral stationary phase. Chromatographia, 31: 55-59.
116. Ochs, H.R., Greenblatt, D.J. and Verburg-Ochs, B. 1985, Ibuprofen kinetics in patients with renal insufficiency who are receiving maintenance hemodialysis. Arthritis and Rheumatism, 28: 1430-1434.
117. Oliary, J., Tod, M., Nicolas, P., Petitjean, O. and Caillé, G. 1992, Pharmacokinetics of ibuprofen enantiomers after single and repeated doses in man. Biopharmaceutics and Drug Disposition, 13: 337-344.
118. Paliwal, J.K., Smith, D.E., Cox, S.R., Berardi, R.R., Dunn-Kucharski, V.A. and Elta, G.H. 1993, Stereoselective, competitive, and non-linear plasma protein binding of ibuprofen enantiomers as determined in vivo in healthy subjects. Journal of Pharmacokinetics and Biopharmaceutics, 21: 145-161.
119. Pettersen, J.E., Ulsaker, G.A. and Jellum, E. 1978, Studies on the metabolism of 2,4βisobutylphenylpropionic acid (ibuprofen) by gas chromatography and mass spectrometry. Dialysis fluid, a convenient medium for studies on drug metabolism. Journal of Chromatography, 145: 413-420.
120. Pirkle, W.H. and Murray, P.G. 1990, The separation of the enantiomers of a variety of non-steroidal anti-inflammatory drugs (NSAIDs) as their anilide derivatives using a chiral stationary phase. Journal of Liquid Chromatography, 13: 2123-2134.
121. Quattrochi, F.P., Robinson, J.D., Curry, R.W., Grieco, M.L. and Schulman, S.G. 1983, The effect of ibuprofen on serum digoxin concentrations. Drug Intelligence and Clinical Pharmacy, 17: 286-288.
122. Radermacher, J., Jentsch, D., Scholl, M.A., Lustinetz, T. and Frölich, J.C. 1991, Diclofenac concentrations after cutaneous application in inflammatory and degenerative joint disease. British Journal of Clinical Pharmacology, 31: 537-541.
123. Ragni, M.V., Miller, B.J., Whalen, R. and Ptachcinski, R. 1992, Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(±) hemophilic men. American Journal of Hematology, 40: 176-182.
124. Reichel, C., Brugger, R., Bang, H., Geisslinger, G. and Brune, K. 1997, Molecular cloning and expression of a 2-arylpropionyl-coenzyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen. Molecular Pharmacology, 51: 576-582.
125. Rekka, E., Ayalogu, E.O., Lewis, D.F., Gibson, G.G. and Ioannides, C. 1994, Induction of hepatic microsomal CYP4A activity and of peroxisomal beta-oxidation by two non-steroidal anti-inflammatory drugs. Archives of Toxicology, 68: 73-78.
126. Rey, E., Pariente-Khayat, A., Gouyet, L., Vauzelle-Kervroedan, F., Pons, G., D'Athis, P., et al. 1994, Stereoselective disposition of ibuprofen enantiomers in infants. British Journal of Clinical Pharmacology, 38: 373-375.
127. Rudy, A.C., Anliker, K.S. and Hall, S.D. 1990, High-performance liquid chromatographic determination of the stereoisomeric metabolites of ibuprofen. Journal of Chromatography, 528: 395-405.
128. Rudy, A.C., Bradley, J.D., Ryan, S.I., Kalasinski, L.A., Xiaotao, Q. and Hall, S.D. 1992, Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients. Therapeutic Drug Monitoring, 14: 464-470.
129. Rudy, A.C., Knight, P.M., Brater, D.C. and Hall, S.D. 1991, Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. Journal of Pharmacology and Experimental Therapeutics, 259: 1133-1139.
130. Rudy, A.C., Knight, P.M., Brater, D.C. and Hall, S.D. 1995, Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment. Journal of Pharmacology and Experimental Therapeutics, 273: 88-93.
131. Sallustio, B.C., Meffin, P.J. and Knights, K.M. 1988, The stereospecific incorporation of fenoprofen into rat hepatocyte and adipocyte triacylglycerols. Biochemical Pharmacology, 37: 1919-1923.
132. Sanins, S.M., Adams, W.J., Kaiser, D.G., Halstead, G.W., Hosley, J., Barnes, H. and Baillie, T.A. 1991, Mechanistic studies on the metabolic chiral inversion of R-ibuprofen in the rat. Drug Metabolism and Disposition, 19: 405-410.
133. Scheuerer, S., Hall, S.D., Williams, K.M. and Geisslinger, G. 1998a, Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. Clinical Pharmacology and Therapeutics, 64: 168-176.
134. Scheuerer, S., Williams, K.M., Brugger, R., McLachlan, A.J., Brune, K., Day, R.O. and Geisslinger, G. 1998b, Effect of clofibrate on the chiral disposition of ibuprofen in rats. Journal of Pharmacology and Experimental Therapeutics, 284: 1132-1138.
135. Schill, G. 1989, High performance ion-pair chromatography. Journal of Biochemical and Biophysical Methods, 18: 249-270.
136. Schneider, H.T., Nürnberg, B., Dietzel, K. and Brune, K. 1990, Biliary elimination of non-steroidal anti-inflammatory drugs in patients. British Journal of Clinical Pharmacology, 29: 127-131.
137. Seideman, P., Lohrer, F., Graham, G.G., Duncan, M.W., Williams, K.M. and Day, R.O. 1994, The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid. British Journal of Clinical Pharmacology, 38: 221-227.
138. Shieh, W.R., Gou, D.M., Liu, Y.C., Chen, C.-S. and Chen, C.-Y. 1993, A 13C NMR study on ibuprofen metabolism in isolated rat liver mitchondria. Analytical Biochemistry, 212: 143-149.
139. Shirley, M.A., Guan, X., Kaiser, D.G., Halstead, G.W. and Baillie, T.A. 1994, Taurine conjugation of ibuprofen in humans and in rat liver in vitro. Relationship to metabolic chiral inversion. Journal of Pharmacology and Experimental Therapeutics, 269: 1166-1175.
140. Skeith, K.J. and Jamali, F. 1991, Clinical pharmacokinetics of drugs used in juvenile arthritis. Clinical Pharmacokinetics, 21: 129-149.
141. Smith, D.A. and Jones, B.C. 1992, Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochemical Pharmacology, 44: 2089-2098.
142. Smith, D.E., Paliwal, J.K., Cox, S.R., Berardi, R.R., Dunn-Kucharski, V.A. and Elta, G.H. 1994, The effect of competitive and non-linear plasma protein binding on the stereoselective disposition and metabolic inversion of ibuprofen in healthy subjects. Biopharmaceutics and Drug Disposition, 15: 545-561.
143. Spraul, M., Hofmann, M., Dvortsak, P., Nicholson, J.K. and Wilson, I.D. 1993, High-performance liquid chromatography coupled to high-field proton nuclear magnetic resonance spectroscopy: application to the urinary metabolites of ibuprofen. Analytical Chemistry, 65: 327-330.
144. Suri, A., Grundy, B.L. and Derendorf, H. 1997, Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. International Journal of Clinical Pharmacology and Therapeutics, 35: 1-8.
145. Tan, S.C., Jackson, S.H., Swift, G.G. and Hutt, A.J. 1997, Stereospecific analysis of the major metabolites of ibuprofen in urine by sequential achiral-chiral high-performance liquid chromatography. Journal of Chromatography B, 53-63.
146. Tegeder, I., Muth-Selbach, U., Lötsch, J., Rüsing, G., Oelkers, R., Brune, K., et al. 1999, Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clinical Pharmacology and Therapeutics, 65: 357-368.
147. Tracy, T.S. and Hall, S.D. 1991, Determination of the epimeric composition of ibuprofenyl-CoA. Analytical Biochemistry, 195: 24-29.
148. Tracy, T.S. and Hall, S.D. 1992, Metabolic inversion of (R)-ibuprofen. Epimerization and hydrolysis of ibuprofenyl-coenzyme A. Drug Metabolism and Disposition, 20: 322-327.
149. Treffel, P. and Gabard, B. 1993, Feasibility of measuring the bioavailability of topical ibuprofen in commercial formulations using drug content in epidermis and a methyl nicotinate skin inflammation assay. Skin Pharmacology, 6: 268-275.
150. Trocóniz, I.F., Armenteros, S., Planelles, M.V., Benítez, J., Calvo, R. and Domínguez, R. 2000, Pharmacokinetic-pharmacodynamic modelling of the antipyretic effect of two formulations of ibuprofen. Clinical Pharmacokinetics, 38: 505-518.
151. Valle-Jones, J.C., Smith, J. and Rowley-Jones, D. 1984, A comparison in general practice of once and twice daily sustained-release ibuprofen and standard ibuprofen in the treatment of non-articular rheumatism. British Journal of Clinical Practice, 38: 353-358.
152. Villanueva, M., Heckenberger, R., Strobach, H., Palmér, M. and Schrör, K. 1993, Equipotent inhibition by R(-)-, S(±)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. British Journal of Clinical Pharmacology, 35: 235-242.
153. Vos, R.M., Mayer, J.M., Etter, J.C. and Testa, B. 1996, Clofibric acid increases the unidirectional chiral inversion of ibuprofen in rat liver preparations. Xenobiotica, 26: 571-582.
154. Wade, L.T., Kenna, J.G. and Caldwell, J. 1997, Immunochemical identification of mouse hepatic protein adducts derived from the non-steroidal anti-inflammatory drugs diclofenac, sulindac and ibuprofen. Chemical Research in Toxicology, 10: 546-555.
155. Wagner, J.G., Albert, K.S., Szpunar, G.J. and Lockwood, G.F. 1984, Pharmacokinetics of ibuprofen in man. IV: Absorption and disposition. Journal of Pharmacokinetics and Biopharmaceutics, 12: 381-399.
156. Walker, J.S., Knihinicki, R.D., Seideman, P. and Day, R.O. 1993, Pharmacokinetics of ibuprofen enantiomers in plasma and suction blister fluid in healthy volunteers. Journal of Pharmaceutical Sciences, 82: 787-790.
157. Walter, K. and Dilger, C. 1997, Ibuprofen in human milk. British Journal of Clinical Pharmacology, 44: 211-212.
158. Wechter, W.J. 1994, Drug chirality: on the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates. Journal of Clinical Pharmacology, 34: 1036-1042.
159. Williams, K.M. 1991, Molecular asymmetry and its pharmacological consequences. Advances in Pharmacology, 22: 57-135.
160. Williams, K.M., Day, R.O. and Breit, S.N. 1993, Biochemical actions and clinical pharmacology of anti-inflammatory drugs. Advances in Drug Research, 24: 121-198.
161. Williams, K.M., Day, R.O., Knihinicki, R.D. and Duffield, A. 1986, The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochemical Pharmacology, 35: 3403-3405.
162. Williams, K.M., Knihinicki, R.D. and Day, R.O. 1991, Pharmacokinetics of the enantiomers of ibuprofen in the rabbit. Agents and Actions, 34: 381-386.
163. Zhao, M.J., Peter, C., Holtz, M.C., Hugenell, N., Koffel, J.C. and Jung, L. 1994, Gas chromatographic- mass spectrometric determination of ibuprofen enantiomers using R(-)-2,2,2-trifluoro-1-(9- anthryl)ethanol as derivatizing agent. Journal of Chromatography B, 656: 441-446.